Does Entresto Improve Survival Rates in Heart Failure Patients?
Yes, Entresto (sacubitril/valsartan) reduces mortality risk in adults with chronic heart failure and reduced ejection fraction (HFrEF). The landmark PARADIGM-HF trial showed it lowered cardiovascular death by 20% compared to enalapril, with all-cause mortality dropping 16% (hazard ratio 0.84; 95% CI 0.76-0.93; p<0.001).[1][2] This benefit held across subgroups, including age, sex, and baseline risk.
How Did the Key PARADIGM-HF Trial Work?
This double-blind, randomized trial enrolled 8,442 HFrEF patients (ejection fraction ≤40%, NYHA class II-IV). Participants received either Entresto (target 97/103 mg twice daily) or enalapril (target 20 mg twice daily). Median follow-up was 27 months. Primary endpoint was cardiovascular death or heart failure hospitalization; Entresto cut this by 20% (HR 0.80; 95% CI 0.73-0.87; p<0.001).[1][3] Mortality gains emerged early and persisted.
What Do Follow-Up Studies Show?
PARAGON-HF (9,476 patients with heart failure and preserved ejection fraction, HFpEF) found no overall mortality benefit (HR 0.95; 95% CI 0.83-1.09), though hospitalization for heart failure dropped 13%.[4] Pooled analyses and real-world data, like the CHAMP-HF registry, confirm PARADIGM-HF survival edges in HFrEF, with consistent 15-20% relative risk reductions.[2][5] No major contradictions in large trials.
Who Benefits Most and Are There Limitations?
Strongest survival gains in HFrEF patients with elevated natriuretic peptides (NT-proBNP > median). Benefits are smaller or absent in HFpEF, acute decompensated failure, or ejection fraction >45%.[1][4] Guidelines (ACC/AHA 2022) recommend Entresto as first-line for HFrEF (class 1, level A evidence).[6]
Common Patient Concerns on Survival and Risks
Patients report better quality of life alongside survival gains, but risks include hypotension (14% vs 9.2% on enalapril), hyperkalemia, and angioedema (0.5%). No excess cancer or renal failure signals in long-term data.[1][7] Survival benefit outweighs risks in eligible patients (NNT ~21 for CV death prevention over 27 months).
How Does Entresto Compare to Other Heart Failure Drugs?
| Drug | Key Trial Mortality Reduction (vs ACEI/ARB) | Best For |
|------|---------------------------------------------|----------|
| Entresto | 16-20% (PARADIGM-HF) [1] | HFrEF, symptomatic |
| Enalapril | Baseline comparator | HFrEF |
| Carvedilol | 34-65% vs placebo (MERIT-HF, COPERNICUS) [8] | HFrEF + beta-blockade |
| Dapagliflozin | 17% (DAPA-HF) [9] | HFrEF/HFpEF |
Entresto outperforms ACEIs alone but pairs well with beta-blockers, MRAs, and SGLT2 inhibitors for additive survival effects.
Sources:
[1] NEJM: PARADIGM-HF (2014)
[2] Lancet: PARADIGM-HF 3-year update (2017)
[3] FDA Label: Entresto
[4] NEJM: PARAGON-HF (2019)
[5] JACC: CHAMP-HF (2018)
[6] ACC/AHA HF Guideline (2022)
[7] ESCardio: Safety meta-analysis (2020)
[8] NEJM: COPERNICUS (2001)
[9] NEJM: DAPA-HF (2019)